Schrödinger logo
Schrödinger SDGR
$ 15.21 1.6%
report update icon

Quarterly report 2026-Q1
added 05-05-2026

Schrödinger Balance Sheet 2025-2011 | SDGR

Brief overview of Schrödinger's balance sheet strength

The review uses the five latest available annual reports between 2021 and 2025.

Assets ended near their starting level at $726.2 million versus $756.5 million. This was preservation of scale rather than expansion.

Liability growth of +81.6% exceeded asset growth of -4%, increasing reliance on outside funding.

The equity ratio reached 50.1% from 73.6%. A high capital share reduces dependence on liabilities.

Cash exceeds interest-bearing debt, producing net debt of -$121.3 million. The balance sheet therefore carries a net cash position.

Cash accounts for 31.7% of assets versus 16.3% initially. The change indicates the degree of financial flexibility.

The accumulated result is -$628.8 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Overall assessment

Schrödinger's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Schrödinger

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-121 M -29.5 M -33.2 M 20.8 M -43.4 M - -11.5 M -77.7 M -9.96 M - - - - - -

Long Term Debt

92.8 M 101 M 111 M 105 M 77.8 M - - - - - - - - - -

Long Term Debt Current

16.4 M 16.8 M 16.9 M 11 M 2.04 M 4.54 M - - - - - - - - -

Total Non Current Liabilities

- - - - - - 204 M 165 M 85.6 M - - - - - -

Total Current Liabilities

189 M 192 M 134 M 109 M 91.2 M 73.2 M - - - - - - - - -

Total Liabilities

362 M 402 M 254 M 241 M 199 M 122 M 249 M 192 M 103 M - - - - - -

Deferred Revenue

113 M 112 M 56.2 M 57.9 M 55.4 M 45.4 M 25.1 M 17.6 M 11 M - - - - - -

Retained Earnings

-629 M -526 M -338 M -379 M -230 M -130 M -105 M -80.5 M -52.1 M - - - - - -

Total Assets

726 M 823 M 803 M 689 M 756 M 746 M 155 M 121 M 58 M - - - - - -

Cash and Cash Equivalents

231 M 147 M 161 M 95.7 M 123 M 203 M 26.5 M 77.7 M - - - - - - -

Book Value

364 M 421 M 549 M 448 M 557 M 624 M -93.3 M -71.6 M -45.4 M - - - - - -

Total Shareholders Equity

364 M 421 M 549 M 448 M 557 M 624 M -93.3 M -71.6 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Schrödinger

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

90.9 M 94.7 M 97.5 M 99.4 M 103 M 107 M 109 M 113 M 107 M 104 M 105 M 87.2 M - 77.4 M 77.8 M 77.1 M 6.43 M 6.84 M 7.22 M 7.22 M 7.22 M 7.22 M 8.89 M 8.89 M 8.89 M 8.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

321 M 332 M 345 M 370 M 220 M 214 M 224 M 231 M 230 M 249 M 241 M 199 M - 189 M 199 M 183 M 112 M 112 M 122 M 122 M 122 M 122 M 57 M 57 M 57 M 57 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

103 M 82.3 M 94.5 M 105 M 41.8 M 40.8 M 49.5 M 43.3 M 46.7 M 51.6 M 57.9 M 43.9 M - 53.8 M 55.4 M 43.9 M 44.1 M 40.8 M 45.4 M 45.4 M 45.4 M 45.4 M 25.1 M 25.1 M 25.1 M 25.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-689 M -661 M -629 M -585 M -485 M -447 M -393 M -308 M -246 M -250 M -379 M -352 M - -264 M -230 M -199 M -164 M -130 M -130 M -130 M -130 M -130 M -105 M -105 M -105 M -105 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

634 M 654 M 688 M 743 M 669 M 688 M 738 M 794 M 842 M 839 M 689 M 662 M - 720 M 756 M 763 M 717 M 744 M 746 M 746 M 746 M 746 M 155 M 155 M 155 M 155 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

260 M 172 M 220 M 338 M 170 M 112 M 135 M 256 M 291 M 238 M 90.5 M 109 M 131 M 121 M 120 M 164 M 118 M 133 M 202 M 202 M 202 M 202 M 26 M 26 M 26 M 26 M 77.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

314 M 321 M 343 M 374 M 449 M 474 M 514 M 564 M 611 M 590 M 448 M 463 M - 531 M 557 M 580 M 606 M 632 M 624 M 624 M 624 M 624 M 98.3 M 98.3 M 98.3 M 98.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

314 M 321 M 343 M 374 M 449 M 474 M 514 M 564 M 611 M 590 M 448 M 463 M 493 M 531 M 557 M 580 M 606 M 632 M 624 M 624 M 624 M 624 M -93.4 M -93.4 M -93.4 M -93.4 M -71.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Schrödinger, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Health information services

Issuer Price % 24h Market Cap Country
Cerner Corporation Cerner Corporation
CERN
- - $ 27.9 B usaUSA
Accolade Accolade
ACCD
- 0.29 % $ 206 M usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
- - $ 119 M usaUSA
Change Healthcare Change Healthcare
CHNG
- - $ 9.03 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
- 4.4 % $ 133 M usaUSA
Covetrus Covetrus
CVET
- - $ 2.94 B usaUSA
Castlight Health, Inc. Castlight Health, Inc.
CSLT
- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
- - $ 6.37 B usaUSA
iCAD iCAD
ICAD
- - $ 102 M usaUSA
Akerna Corp. Akerna Corp.
KERN
- - $ 161 M usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
- -10.39 % $ 886 M usaUSA
MTBC MTBC
MTBC
- -0.58 % $ 51.7 M usaUSA
HealthEquity HealthEquity
HQY
$ 98.69 4.28 % $ 8.5 B usaUSA
1Life Healthcare 1Life Healthcare
ONEM
- - $ 3.37 B usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
- - $ 1.6 B usaUSA
Premier Premier
PINC
- - $ 2.33 B usaUSA
American Well Corporation American Well Corporation
AMWL
$ 11.12 2.11 % $ 178 M usaUSA
R1 RCM R1 RCM
RCM
- - $ 3.81 B usaUSA
Signify Health Signify Health
SGFY
- -0.02 % $ 7.21 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
- - $ 21.4 M usaUSA
NantHealth NantHealth
NH
- -46.64 % $ 10.4 M usaUSA
SCWorx Corp. SCWorx Corp.
WORX
- - $ 7.71 M usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
- - $ 255 M usaUSA
So-Young International So-Young International
SY
- - $ 156 M chinaChina
Progyny Progyny
PGNY
$ 31.68 1.57 % $ 2.7 B usaUSA
Phreesia Phreesia
PHR
$ 10.73 4.84 % $ 641 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
$ 3.03 2.36 % $ 1.08 B usaUSA
Omnicell Omnicell
OMCL
$ 41.83 2.02 % $ 1.92 B usaUSA
Health Catalyst Health Catalyst
HCAT
$ 2.17 4.33 % $ 152 M usaUSA
HealthStream HealthStream
HSTM
$ 27.79 - $ 834 M usaUSA
Evolent Health Evolent Health
EVH
$ 3.97 -5.93 % $ 453 M usaUSA
Zhongchao Zhongchao
ZCMD
$ 1.23 -12.29 % $ 4.2 M chinaChina
Teladoc Health Teladoc Health
TDOC
- - $ 1.56 B usaUSA
10x Genomics 10x Genomics
TXG
$ 45.9 -0.8 % $ 5.73 B usaUSA
Veeva Systems Veeva Systems
VEEV
$ 197.58 6.08 % $ 32.3 B usaUSA